Cargando…

CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a genetically heterogeneous subtype of B-cell ALL characterized by chromosomal rearrangements and mutations that result in aberrant cytokine receptor and kinase signaling. In particular, chromosomal rearrangements resulting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyer, Lauren K., Delgado-Martin, Cristina, Maude, Shannon L., Shannon, Kevin M., Teachey, David T., Hermiston, Michelle L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6638974/ https://www.ncbi.nlm.nih.gov/pubmed/31318944 http://dx.doi.org/10.1371/journal.pone.0220026

Ejemplares similares

Characterisation of the genomic landscape of CRLF2‐rearranged acute lymphoblastic leukemia
por: Russell, Lisa J., et al.
Publicado: (2017)

Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia
por: Mittelman, Steven D., et al.
Publicado: (2021)

High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement
por: Ge, Zheng, et al.
Publicado: (2016)

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias
por: Delgado-Martin, C, et al.
Publicado: (2017)

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
por: Tsuzuki, Shinobu, et al.
Publicado: (2022)

Inhibition of the Sec61 translocon overcomes cytokine‐induced glucocorticoid resistance in T‐cell acute lymphoblastic leukaemia
por: Meyer, Lauren K., et al.
Publicado: (2022)

Multiparametric flow cytometry directing the evaluation of CRLF2 rearrangements and JAK2 status in pediatric B cell precursor acute lymphoblastic leukemia
por: Noronha, Elda Pereira, et al.
Publicado: (2023)

TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia
por: Alkashgari, Hossam R., et al.
Publicado: (2022)

Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia
por: Sarno, Jolanda, et al.
Publicado: (2023)

P344: ONCOGENESIS OF CRLF2 OVEREXPRESSION AND EFFECT OF A NOVEL JAK2 INHIBITOR IN CRLF2 OVEREXPRESSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Gu, Yan, et al.
Publicado: (2023)

Potential efficacy and prognosis of silencing the CRLF2-mediated AKT/mTOR pathway in pediatric acute B-cell lymphoblastic leukemia
por: Jiang, Min, et al.
Publicado: (2019)

Clinical characterization and prognosis of T cell acute lymphoblastic leukemia with high CRLF2 gene expression in children
por: Wang, Mingmin, et al.
Publicado: (2019)

The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia
por: Meyer, Lauren K., et al.
Publicado: (2019)

The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities
por: Meyer, Lauren K., et al.
Publicado: (2019)

Single cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia
por: Potter, N, et al.
Publicado: (2018)

Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia
por: Vesely, C, et al.
Publicado: (2017)

Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol
por: Olivas-Aguirre, Miguel, et al.
Publicado: (2021)

CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia
por: Palmi, Chiara, et al.
Publicado: (2016)

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia
por: Sarno, Jolanda, et al.
Publicado: (2018)

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia
por: Zhang, Qi, et al.
Publicado: (2018)

Gain of chromosome 21 increases the propensity for P2RY8: :CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression
por: Page, Elyse C., et al.
Publicado: (2023)

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations
por: Kerstjens, Mark, et al.
Publicado: (2016)

CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways
por: Moreno Lorenzana, Dafné, et al.
Publicado: (2021)

Poor outcome of pediatric B-cell acute lymphoblastic leukemia associated with high level of CRLF2 gene expression in distinct molecular subtypes
por: Lin, Danna, et al.
Publicado: (2023)

GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy
por: Heidari, N, et al.
Publicado: (2010)

Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL
por: Tian, Ze, et al.
Publicado: (2023)

Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia
por: Soh, Sheila Xinxuan, et al.
Publicado: (2014)

The prognostic value of glucocorticoid receptors for adult acute lymphoblastic leukemia
por: Bedewy, Ahmed M. L., et al.
Publicado: (2015)

Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia
por: Goossens, Steven, et al.
Publicado: (2016)

P1421: BIMODAL TARGETING OF CYTOKINE RECEPTOR-LIKE FACTOR 2 (CRLF2) WITH JAK INHIBITION AND CHIMERIC ANTIGEN RECEPTOR T CELL IMMUNOTHERAPY IN DOWN SYNDROME ACUTE LYMPHOBLASTIC LEUKEMIA
por: Bagashev, A., et al.
Publicado: (2022)

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia
por: Canté-Barrett, K, et al.
Publicado: (2016)

Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
por: Follini, Elena, et al.
Publicado: (2019)

Salidroside overcomes dexamethasone resistance in T-acute lymphoblastic leukemia cells
por: Niu, Ya-Na, et al.
Publicado: (2021)

CRLF1 and CLCF1 in Development, Health and Disease
por: Crisponi, Laura, et al.
Publicado: (2022)

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
por: Kuwatsuka, Y, et al.
Publicado: (2011)

Molecular Cytogenetic Analysis of Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia
por: Woo, Hee Yeon, et al.
Publicado: (2005)

The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias
por: Andersson, Anna K, et al.
Publicado: (2015)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

IKZF1 deletions associate with CRLF2 overexpression leading to a poor prognosis in B-cell precursor acute lymphoblastic leukaemia
por: Maciel, Ana Luiza Tardem, et al.
Publicado: (2021)

Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment
por: Dyczynski, Matheus, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m8l158mlt3ugsjn9k65ji694l9